Archived research. Equity forecasting is part of the Runchey Research archive (methodology era 1) and is no longer actively updated. Everything remains published at its original URL. Browse the archive
Will DOW stock close above $50.00 on any trading day before December 31, 2026?
Current Prediction
Prediction History
Q2 2026 EBITDA guide $2.0B + pricing ladder (Apr $0.30/lb settled, May $0.20/lb announced) + Middle East supply disruption expected to persist through 2026 pull mid-cycle earnings forward. 30% appreciation to $50 plausible over 8 months given guide and pricing catalysts.
Why This Question Matters
A DOW close above $50 would be a cycle-inflection signal and would validate myth-meter's DEMANDING-but-achievable expectations classification. At $38.51, the committee priced a ~7x multiple on mid-cycle EBITDA of $5.5-6B. A move to $50 implies either multiple re-rating on cycle visibility or Upside Compound scenario (E, 15-25% probability per Black Swan Beacon). Failure to reach $50 by year-end would corroborate the NARRATIVE_REALITY_GAP = DISCONNECTED finding and suggest $2-8/share of narrative froth may unwind.
Prediction Distribution
Individual Predictions(9 runs)
Stock at $38.53 needs ~30% appreciation to cross $50 by Dec 31 2026. Q2 guide of $2.0B EBITDA (vs baseline pricing $5.5-6B mid-cycle) implies the market is already below where disclosed fundamentals point. If Q2 prints near guide and H2 T2O run-rate materializes, a re-rating to $50+ is the base case not a tail. EV/EBITDA 6.0x on $7B FY26 = $42B EV = ~$28/share equity before net debt — so multiple expansion also required. Probability 0.62.
The baseline 0.30 was anchored to '$50 requires cycle-peak validation on 2-3 year timeline'. Q1 + Q2 guide compresses that timeline. However, geopolitical duration risk remains — if Hormuz reopens by Q3 2026, pricing reversal compresses multiple. Probability 0.58.
Chemicals historically lag EBITDA inflection in multiple expansion — investors wait for proof points. Q2 print mid-July 2026 is the key test. Between now and year-end there are two quarterly prints (Q2, Q3). If both validate, stock likely above $50. If Q3 shows reversal signs, trajectory stalls. 50-55%.
Q1 earnings print (released 2026-04-23 BMO) likely drives strong intraday move. Stock at $38.53 pre-open. Pattern for beat + raise guidance in chemicals is +8-15% single-day move, implying $42-44 close day 1. Remaining path to $50 over 8 months requires another 15% appreciation. Plausible with Q2 print execution. Probability 0.60.
Market typically prices Q2 guide partially through Q2, with confirmation driving gains. Pricing ladder settling also provides visible catalysts (May $0.20 PE settlement). Path to $50 by Dec 31 is realistic if Middle East disruption persists. 0.58.
Chemicals cycles often over-deliver short-term but disappoint medium-term as supply responds. $50 by year-end requires sustained narrative, continued pricing power, no rapid peace deal. 55%.
Q1 beat + Q2 guide $2B + pricing momentum = stock appreciation path clear. 30% needed, plausible in 8 months.
Path to $50 realistic but not certain. Execution + pricing momentum must hold. 55%.
Baseline 0.30 insufficient given Q2 $2B guide. Updated 0.58 reflects new trajectory.
Resolution Criteria
Resolves YES if DOW's official closing price on NYSE equals or exceeds $50.00 on any trading day from 2026-04-22 through 2026-12-31 inclusive. Resolves NO if DOW fails to close at or above $50.00 on any day in the window.
Resolution Source
NYSE official closing prices (Bloomberg, Yahoo Finance, Google Finance)
Source Trigger
DOW stock > $50 by 2026-12-31 (cycle inflection signal; validates DEMANDING expectations)
Full multi-lens equity analysis